Telma LN 40 mg Tablet

Telma LN 40mg tablet is a prescription based medication approved by healthcare professional. It is used to help manage high blood pressure (hypertension) in adults by relaxing blood vessels, allows blood to flow more easily and help reduce the risk of heart attack, stroke and kidney problems.

Its active ingredient is Clinidipine in 10mg concentration and Telmisartan in 40mg concentration that belongs to the drug class in a combination of Angiotensin II receptor blocker (ARB) and Calcium channel blocker.

Doctor recommend this medicine as a first line therapy to manage the disease well. Do not self administer the medication without consultation with a healthcare professional.

Manage high blood pressure

Always follow doctor prescription as Telma LN tablet cause various side effects based on the patient overall health condition and response to the treatment.

Common symptoms include:

• Tiredness
  
• Feeling sleepy
  
• Headaches
  
• Back pain
  
• Difficulty in breathing
  
• Stomach upset
  
• Nausea
  
• Muscle pain
  
• Swelling of ankles and feet
  
• Dizziness
  
• vision change
  
• palpitation
  
• Fever
  
• Increased potassium level
  

• Telma LN 40mg tablet dosage and duration is correctly administered by the healthcare professional.
• The medicine should be taken orally with a whole glass of water.
• Do not crush, chew or break the tablet as it may affect the way the medicine works in the body.
• Never self administer the medication as improper use can lead to serious side effects and complications.
  

• Telma LN 40mg tablet is first line therapy with two active drugs Telmisartan that blocks angiotensin II, a hormone that narrows blood vessels.
• While Clinidipine blocks calcium movement into the smooth muscle of blood vessels, causing them to relax and widen.
• They both work together to lower blood pressure, reduce the heart's workload and help protect viral organs like the heart, brain and kidney from damaged caused by uncontrolled hypertension.
  

• Chandra, K. S., & Ramesh, G. (2013). The fourth-generation Calcium channel blocker: cilnidipine. Indian heart journal, 65(6), 691-695.
  
• Takahara, A. (2009). Cilnidipine: a new generation Ca2+ channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovascular therapeutics, 27(2), 124-139.
  
• Shete, M. M. (2016). Cilnidipine: next generation calcium channel blocker. J Assoc Physicians India, 64(4), 95-99.
  
• Deppe, S., Böger, R. H., Weiss, J., & Benndorf, R. A. (2010). Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert opinion on drug metabolism & toxicology, 6(7), 863-871.
  
• Destro, M., Cagnoni, F., Dognini, G. P., Galimberti, V., Taietti, C., Cavalleri, C., & Galli, E. (2011). Telmisartan: just an antihypertensive agent? A literature review. Expert opinion on pharmacotherapy, 12(17), 2719-2735.​